Analysed CHARLES RIVER LABORATORIES (CRL:NYSE) News Sources
Charles River (CRL) Reliance on International Sales: What Investors Need to Know
11-05-2026
yahoo.com
CRL Q1 Deep Dive: Portfolio Restructuring and Cost Initiatives Set Stage for Margin Expansion
11-05-2026
yahoo.com
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
13-05-2026
yahoo.com
[Latest] Global Transgenic Animals Market Size/Share Worth USD 7.89 Billion by 2035 at a 10.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
14-05-2026
yahoo.com
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
17-05-2026
yahoo.com
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call
18-05-2026
yahoo.com
Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
20-05-2026
yahoo.com
Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services?
24-05-2026
yahoo.com
What is the current price of CHARLES RIVER LABORATORIES (CRL:NYSE)?
The current price of CHARLES RIVER LABORATORIES (CRL:NYSE) is $183.57.
CHARLES RIVER LABORATORIES (CRL:NYSE) absolute price change since previous trading day?
The absolute price change of CHARLES RIVER LABORATORIES (CRL:NYSE) since the previous trading day is $19.08.
CHARLES RIVER LABORATORIES (CRL:NYSE) percentage price change since previous trading day?
The percentage price change of CHARLES RIVER LABORATORIES (CRL:NYSE) since the previous trading day is 11.5995%.
What is the most recent average sentiment score for CHARLES RIVER LABORATORIES (CRL:NYSE)?
The most recent average sentiment score for CHARLES RIVER LABORATORIES (CRL:NYSE) is 72 out of 100.
What is the most recent average sentiment for CHARLES RIVER LABORATORIES (CRL:NYSE)?
The most recent sentiment for CHARLES RIVER LABORATORIES (CRL:NYSE) is .
SEC-8K** Filing Available For CHARLES RIVER LABORATORIES (CRL:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.